These data suggest that inhibitors of PI 3-kinase, PKB, or rapalogs that inhibit mTORC1 signalling, are unlikely to be effective in mtKRAS tumours, as these pathways are refractory to activation. This evidence concerns the gene AKT1 and neoplasm.